Who is moving to which position
Resolved 28 March 2026Incoming appointee
1 itemShimizu Takafumi (清水 崇文) has practical experience in the Company’s Corporate Planning Department and possesses particularly strong expertise in the medical field and overseas business. He also has management experience at StemCell Institute. In addition, he has a deep understanding of the operations and management strategy of the Company Group, enabling him to make management decisions from an overall perspective of the Group’s business. As he is expected to contribute to highly transparent decision-making and the strengthening of the governance structure, the Company has selected him as a director.
| Item | Details |
|---|---|
| Resolution date | 28 March 2026 |
| Scheduled Appointment Date | Late June 2026 (to be formally decided following approval at the Annual General Meeting of Shareholders scheduled for late June 2026) |
| Name of appointee | Shimizu Takafumi (清水 崇文) |
| Appointee's new position | Director (part-time) |
| Appointee's previous position | Representative Director and President, StemCell Institute (currently in office) |
| Appointee's date of birth | 17 March 1973 |
| Year the appointee joined the Company | 1998 |
| Reasons for appointment | Shimizu Takafumi (清水 崇文) has practical experience in the Company’s Corporate Planning Department and possesses particularly strong expertise in the medical field and overseas business. He also has management experience at StemCell Institute. In addition, he has a deep understanding of the operations and management strategy of the Company Group, enabling him to make management decisions from an overall perspective of the Group’s business. As he is expected to contribute to highly transparent decision-making and the strengthening of the governance structure, the Company has selected him as a director. |
| Subject to Approval by the General Meeting of Shareholders | Required. Approval of the proposal to select the candidate for new director at the Annual General Meeting of Shareholders scheduled for late June 2026 is required. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Shimizu Takafumi (清水 崇文) has practical experience in the Company’s Corporate Planning Department, expertise in the medical field and overseas business, and management experience at StemCell Institute. He is expected to contribute to management decisions from an overall perspective of the business, highly transparent decision-making, and the strengthening of the governance structure by drawing on his understanding of the operations and management strategy of the Company Group.